ADCs are a targeted approach to the treatment of cancer, and as ever more of these complex products enter clinical development, the need to scale up production of their payloads becomes a pressing topic. In this webinar, participants will hear about Lonza’s investment in facilities capable of producing large quantities (100+ kg) under the strictest levels of containment.
Watch now to learn more about:
- Key market trends
- Lonza’s approach to lifecycle investment
- Leadership in HPAPI facility & process design
Who should watch on-demand:
- Key clients / potential clients from the ADC arena, covering all disciplines from biologics/ bioconjugation and payload-linker